|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities
This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.
Lung cancer is the second most common malignancy in the US, but the most common cause of cancer-related deaths. The management of SCLC and NSCLC is complex and staying up-to-date on the screening, diaganosis and treatment options is crucial for the specialty pharmacist caring for these patients. This activity includes a patient case study to help thoroughly explore the challenges with this disease.
The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:
- Describe the epidemiology, risk factors, pathology, and etiology of lung cancer.
- Discuss diagnosis and staging of both SCLC and NSCLC.
- Outline the role of targeted agents in the treatment of lung cancer.
- Discuss patient support, adherence, adverse effects monitoring and Pharmacist role.
- Apply treatment guidelines in patient case-study situations.
Angie Wood, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Angie Wood does not have any relevant commercial and/or financial relationships to disclose.
Release Date: 08-05-2019
Expiration Date: 08-05-2022
This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-189-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.5 contact hour (0.15 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.